Decitabine
Phase 2Completed 1 views this week 0 watching💤 Quiet
Interest: 35/100
35
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Acute Myelogenous Leukemia
Conditions
Acute Myelogenous Leukemia, Myelodysplastic Syndrome
Trial Timeline
Jul 1, 2005 → Feb 1, 2008
NCT ID
NCT00760084About Decitabine
Decitabine is a phase 2 stage product being developed by Eisai for Acute Myelogenous Leukemia. The current trial status is completed. This product is registered under clinical trial identifier NCT00760084. Target conditions include Acute Myelogenous Leukemia, Myelodysplastic Syndrome.
What happened to similar drugs?
20 of 20 similar drugs in Acute Myelogenous Leukemia were approved
Approved (20) Terminated (4) Active (0)
✅Modification of Prasugrel based on a biological assay + prasugrel / clopidogrelDaiichi SankyoApproved
Hype Score Breakdown
Clinical
12
Activity
8
Company
15
Novelty
0
Community
0
Clinical Trials (8)
| NCT ID | Phase | Status |
|---|---|---|
| NCT00538876 | Phase 1 | Completed |
| NCT00477386 | Phase 1/2 | Completed |
| NCT00398983 | Phase 2/3 | Completed |
| NCT00349596 | Phase 1 | Completed |
| NCT00760084 | Phase 2 | Completed |
| NCT00260065 | Phase 2 | Completed |
| NCT00358644 | Phase 2 | Completed |
| NCT00113321 | Phase 2 | Terminated |
Competing Products
20 competing products in Acute Myelogenous Leukemia